ZA202006092B - Imidazopiperazine inhibitors of transcription activating proteins - Google Patents
Imidazopiperazine inhibitors of transcription activating proteinsInfo
- Publication number
- ZA202006092B ZA202006092B ZA2020/06092A ZA202006092A ZA202006092B ZA 202006092 B ZA202006092 B ZA 202006092B ZA 2020/06092 A ZA2020/06092 A ZA 2020/06092A ZA 202006092 A ZA202006092 A ZA 202006092A ZA 202006092 B ZA202006092 B ZA 202006092B
- Authority
- ZA
- South Africa
- Prior art keywords
- imidazopiperazine
- inhibitors
- activating proteins
- transcription activating
- transcription
- Prior art date
Links
- FGLBAPOBZMMFAK-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-imidazo[4,5-b]pyrazine Chemical compound N1CCNC2=C1N=CN2 FGLBAPOBZMMFAK-UHFFFAOYSA-N 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000035897 transcription Effects 0.000 title 1
- 238000013518 transcription Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650151P | 2018-03-29 | 2018-03-29 | |
| PCT/US2019/024976 WO2019191667A1 (en) | 2018-03-29 | 2019-03-29 | Imidazopiperazine inhibitors of transcription activating proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202006092B true ZA202006092B (en) | 2022-11-30 |
Family
ID=68057632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/06092A ZA202006092B (en) | 2018-03-29 | 2020-10-01 | Imidazopiperazine inhibitors of transcription activating proteins |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11058688B2 (https=) |
| EP (1) | EP3773587A4 (https=) |
| JP (1) | JP7387627B2 (https=) |
| KR (1) | KR102815607B1 (https=) |
| CN (1) | CN112165944B (https=) |
| AU (2) | AU2019245403B2 (https=) |
| BR (1) | BR112020019824A2 (https=) |
| CA (1) | CA3095367A1 (https=) |
| IL (1) | IL277628A (https=) |
| RU (1) | RU2020131507A (https=) |
| WO (1) | WO2019191667A1 (https=) |
| ZA (1) | ZA202006092B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019245403B2 (en) | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| AU2021259814B2 (en) * | 2020-04-25 | 2023-09-28 | Pharmablock Sciences (Nanjing), Inc. | CBP/EP300 inhibitor and use thereof |
| JP7777131B2 (ja) * | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| WO2022072648A1 (en) * | 2020-10-02 | 2022-04-07 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| KR102910851B1 (ko) * | 2021-04-21 | 2026-01-09 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도 |
| CN113429427A (zh) * | 2021-07-05 | 2021-09-24 | 湖南南新制药股份有限公司 | 杂环化合物及其制备方法和药物用途 |
| CN115724857B (zh) * | 2021-08-25 | 2024-06-21 | 杭州禹泓医药科技有限公司 | 一种芳杂环类化合物、含其的药物组合物及其应用 |
| CN116410211A (zh) * | 2021-12-29 | 2023-07-11 | 山东新时代药业有限公司 | 一种苯并呋喃类化合物 |
| TW202340164A (zh) * | 2022-01-21 | 2023-10-16 | 大陸商深圳默元生物科技有限公司 | Ｎ－羥基喹啉甲醯胺化合物及其用途 |
| WO2023235809A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | Cgas inhibitors |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1537114B8 (en) | 2002-08-07 | 2007-10-03 | Novartis AG | Organic compounds as agents for the treatment of aldosterone mediated conditions |
| AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| MX2008015008A (es) | 2006-05-26 | 2008-12-05 | Novartis Ag | INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA. |
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| ATE545647T1 (de) | 2006-12-22 | 2012-03-15 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazoä1,5-aüpyrazinderivat |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| EP2170350B1 (en) | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| KR20110036069A (ko) | 2008-06-25 | 2011-04-06 | 액테리온 파마슈티칼 리미티드 | 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물 |
| EA021293B1 (ru) * | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP2528918B1 (en) | 2010-01-29 | 2014-09-10 | Nerviano Medical Sciences S.r.l. | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| CN103087067A (zh) * | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途 |
| EP2920173B1 (en) | 2012-10-18 | 2016-11-23 | Bristol-Myers Squibb Company | Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists |
| WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| JP2016525503A (ja) * | 2013-06-28 | 2016-08-25 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| WO2016055028A1 (en) | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| US9763922B2 (en) * | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| MA45122A (fr) | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| EP3464286B1 (en) * | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| AU2019245403B2 (en) | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
-
2019
- 2019-03-29 AU AU2019245403A patent/AU2019245403B2/en active Active
- 2019-03-29 CA CA3095367A patent/CA3095367A1/en active Pending
- 2019-03-29 EP EP19777484.7A patent/EP3773587A4/en active Pending
- 2019-03-29 BR BR112020019824-2A patent/BR112020019824A2/pt not_active Application Discontinuation
- 2019-03-29 WO PCT/US2019/024976 patent/WO2019191667A1/en not_active Ceased
- 2019-03-29 JP JP2020551963A patent/JP7387627B2/ja active Active
- 2019-03-29 CN CN201980035368.2A patent/CN112165944B/zh active Active
- 2019-03-29 US US16/370,404 patent/US11058688B2/en active Active
- 2019-03-29 RU RU2020131507A patent/RU2020131507A/ru unknown
- 2019-03-29 KR KR1020207031004A patent/KR102815607B1/ko active Active
-
2020
- 2020-09-27 IL IL277628A patent/IL277628A/en unknown
- 2020-10-01 ZA ZA2020/06092A patent/ZA202006092B/en unknown
-
2021
- 2021-05-21 US US17/327,217 patent/US12186324B2/en active Active
-
2024
- 2024-11-06 US US18/938,730 patent/US20250127792A1/en active Pending
-
2025
- 2025-04-29 AU AU2025202971A patent/AU2025202971A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020019824A2 (pt) | 2021-01-05 |
| EP3773587A4 (en) | 2021-09-29 |
| KR20210003764A (ko) | 2021-01-12 |
| JP7387627B2 (ja) | 2023-11-28 |
| US20190298729A1 (en) | 2019-10-03 |
| CN112165944A (zh) | 2021-01-01 |
| US20230008047A1 (en) | 2023-01-12 |
| RU2020131507A (ru) | 2022-05-04 |
| CN112165944B (zh) | 2024-04-09 |
| AU2019245403A1 (en) | 2020-10-22 |
| US20250127792A1 (en) | 2025-04-24 |
| US11058688B2 (en) | 2021-07-13 |
| CA3095367A1 (en) | 2019-10-03 |
| AU2025202971A1 (en) | 2025-05-15 |
| US12186324B2 (en) | 2025-01-07 |
| JP2021519308A (ja) | 2021-08-10 |
| IL277628A (en) | 2020-11-30 |
| AU2019245403B2 (en) | 2025-02-06 |
| KR102815607B1 (ko) | 2025-05-30 |
| EP3773587A1 (en) | 2021-02-17 |
| WO2019191667A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006092B (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| IL275333B1 (en) | Inhibitors of fibroblast activation protein | |
| IL281939A (en) | VAP-1 inhibitors | |
| SG11202106304RA (en) | Irreversible inhibitors of menin-mll interaction | |
| IL261606A (en) | Inhibitors of transfected menin-mll and methods of use | |
| ZA201805879B (en) | Inhibitors of wdr5 protein-protein binding | |
| IL304110A (en) | Keap1–nrf2 protein–protein interaction inhibitors | |
| SG11202012529VA (en) | Means and methods for increased protein expression by use of transcription factors | |
| EP3558998A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL274504A (en) | 2ACSS inhibitors and methods of their use | |
| EP3099800A4 (en) | Expression and purification of crm197 and related proteins | |
| EP3142652A4 (en) | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | |
| EP3664822A4 (en) | MICROBIAL INDUCED AMYLOID FORMATION INHIBITORS | |
| IL281815A (en) | VAP-1 inhibitors | |
| EP3749365A4 (en) | PEPTIDY INHIBITORS OF THE CALCINEURIN-NFAT INTERACTION | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| EP3271379A4 (en) | Grp94 derived polypeptides for inhibiting pcsk9 and methods of use | |
| SG11202000621VA (en) | Inhibitors of ror? | |
| GB201709136D0 (en) | New therapeutic uses of enzyme inhibitors | |
| EP3268011A4 (en) | DEK PROTEIN INHIBITORS AND ASSOCIATED METHODS | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| SG11202101817UA (en) | Methods of inhibition | |
| HK40047154A (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| AU2018901681A0 (en) | Inhibitors of necroptosis |